West Pharma Q1 net sales $720M (+7.4%), adj. EPS $2.30; raises FY2022 adj. EPS guidance

WEST PHARMACEUTICAL SERVICES INC

2022-Q1 EPS reported $2.29 revenue$720,000,000

Net sales $720.0M (+7.4% YoY); organic sales growth 11.0%.
Reported diluted EPS $2.29 (+15.1%), adjusted diluted EPS $2.30 (+12.2%).
Raises FY2022 adjusted EPS guidance to $9.30-$9.45 from $9.20-$9.35; reaffirms net sales $3.05B-$3.075B.
Q3 dividend $0.18/share, payable Aug 3, record Jul 20; repurchased 390k shares for $147.1M.
Proprietary Products segment sales $601.3M (+10.6%); HVP organic growth double-digit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.